Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effectiveness of Cannabis in the Treatment of Tinnitus Patients

This study has suspended participant recruitment.
Information provided by (Responsible Party):
Oron Yahav, Wolfson Medical Center Identifier:
First received: October 14, 2013
Last updated: December 19, 2015
Last verified: December 2015
The hypothesis of the study is that the use of Cannabis will attenuate the tinnitus level as experienced by the patients.

Condition Intervention Phase
Drug: Cannabis
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 1 Study to Study the Efficacy and Safety of Cannabis in the Treatment of Tinnitus

Resource links provided by NLM:

Further study details as provided by Wolfson Medical Center:

Primary Outcome Measures:
  • Tinnitus handicap inventory score [ Time Frame: 2 months ] [ Designated as safety issue: No ]
    Patients will be monitored during a month (treatment time) and a month later

Estimated Enrollment: 20
Study Start Date: December 2013
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cannabis
Treatment with a Cannabis capsule
Drug: Cannabis
Cannabis capsules given once daily for a month
Placebo Comparator: Placebo
Drug: Placebo


Ages Eligible for Study:   30 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Tinnitus lasting more than 3 months
  • Tinnitus Handicap Inventory score over 58
  • Treated previously for tinnitus (2 modalities)

Exclusion Criteria:

  • Prior use of drugs
  • Current use of Cannabis
  • Neurologic or Psychiatric disease
  • Heart Failure
  • Ischemic Heart Disease
  • Immune Deficiency
  • Acoustic Neuroma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01969474

Wolfson Medical Centre
Holon, Israel
Sponsors and Collaborators
Wolfson Medical Center
  More Information

Responsible Party: Oron Yahav, MD, Wolfson Medical Center Identifier: NCT01969474     History of Changes
Other Study ID Numbers: 1.01 
Study First Received: October 14, 2013
Last Updated: December 19, 2015
Health Authority: Israel: Ministry of Health

Keywords provided by Wolfson Medical Center:
Tinnitus Cannabis

Additional relevant MeSH terms:
Marijuana Abuse
Hearing Disorders
Ear Diseases
Otorhinolaryngologic Diseases
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders processed this record on October 21, 2016